Mergers & Acquisitions ·
Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics, to develop next-generation menin inhibitors for…
KURAKura Oncology, Inc.
Kura Oncology formed a wholly owned subsidiary, Caspian Therapeutics, to develop next-generation menin inhibitors for diabetes and cardiometabolic diseases. On September 8, 2026, Caspian completed a private financing of $50.0 million in Series A preferred stock, with Kura Oncology investing $4.3 million. Following the transaction, Kura holds approximately 49.2% of Caspian's outstanding capital stock. The Company also entered into a Contribution and License Agreement to transfer rights for compounds like KO-7246 to Caspian in exchange for common stock and up to $1.5 million in cost reimbursement. Additionally, an intercompany services agreement was executed for research and administrative support. Kura Oncology operates in the biotechnology industry, focusing on the discovery and development of targeted therapies for cancer.